基本信息
views: 8
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
The study of extracellular vesicles (EVs) and exosome-based tumor pathogenesis, biomarkers and derivative therapeutics comprise the primary research interests of our laboratory. Small EVs (sEVs), originally termed exosomes, are naturally occurring biological nanovesicles ~30-150 nm in size. They are constitutively generated and released into the surrounding extracellular matrix and circulation. They have been shown to participate in cell-to-cell communication such as receptor and RNA transport between cells. Tumor sEVs participate in tumor-mediated angiogenesis, immune suppression and growth.
In past investigations we discovered that melanoma sEVs prepare lymph nodes for metastasis by establishing pre-metastatic niches. We are continuing to build on this finding by investigating the influence of tumor sEVs on endothelial- and macrophage-mediated tumor supportive inflammatory processes.
The results of our basic science investigations are being used to guide the development of personalized EV-based biomarkers through collaborations within our department of Pharmacology and Toxicology, the UofL Hepatobiology and Toxicology COBRE, the Brown Cancer Center (BCC) colleagues, outside Universities and Biotechnology Companies. Biomarker discovery efforts are supported in part through research into the development of “label free” microfluidic exosome detection, isolation and collection technologies in collaboration with mechanical engineers. High throughput and high volume microfluidic machines will be used to facilitate the collection and banking of EV subtypes for biorepositories.
Such technologies also support the long term translational goals of the lab to design and translate personalized EV-based therapeutics. This includes developing means to convert EVs into biocompatible nanocarriers able to carry a variety of therapeutic payloads to target and treat tumor microenvironments for melanoma, lung cancer, or other cancer types. Current EV therapies being pursued in the lab include lung cancer and melanoma sEV-based immunotherapeutics and tumor sEV vaccines.
Research Interests
Papers共 44 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ASPET 2024 Annual Meeting Abstract - Cancer Pharmacology (2024)
Alaijah Bashi,Cecilia Lekpor,Joshua L. Hood,Winston E. Thompson,Jonathan K. Stiles,Adel Driss, Tamas Visnovitz
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESno. 23 (2023): 16934
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)
Ryan P. McNamara,Hannah M. McMillan, Blanca V. Rodriguez, James, Erickson,Heather Branscome,Sarah Al Sharif,Ribhav Mishra,Kathleen M Lennon,Amy H. Lee, C. Jean, Lee,
semanticscholar(2021)
Load More
Author Statistics
#Papers: 41
#Citation: 2679
H-Index: 21
G-Index: 29
Sociability: 5
Diversity: 3
Activity: 21
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn